NovaBridge Biosciences NBP
Annual
Quarterly
FY2023 · ended Dec 31, 2023 · Revenue $632,000, +140.7% YoY · Filed Apr 7, 2026
NovaBridge Biosciences (NBP) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$20.6 million. As of Dec 31, 2025 it held $210.8 million in cash and investments and $3.1 million in total debt.
Revenue
$632,000
+140.7% vs prior year
Net income
$-46.27M
-108.1% vs prior year
Operating cash flow
$-20.60M
+60.9% vs prior year
Free cash flow
$-20.60M
+60.9% vs prior year
EPS
$-0.21
-75.0% vs prior year
Dividend per share
None
Shares outstanding
265.38M
+41.6% vs prior year
Net cash
$207.78M
FY 2025
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NBP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Rockville, MD
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1778016
- Former names
- I-Mab (until Oct 28, 2025)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | $632,000 | -$1.6M | $13.8M |
| Operating income | -$94.3M | -$51.4M | — | — | — |
| Net income | -$46.3M | -$22.2M | -$207.7M | -$371.1M | -$365.9M |
| Diluted EPS | -$0.21 | -$0.12 | -$1.09 | -$1.96 | -$2.09 |
| Operating cash flow | -$20.6M | -$52.7M | -$183.8M | -$159.9M | -$152.7M |
| Free cash flow | -$20.6M | -$52.7M | -$184.0M | -$162.0M | -$157.4M |
| Total assets | $260.5M | $212.7M | $368.9M | $590.6M | $878.9M |
| Total liabilities | $29.6M | $11.5M | $126.3M | $168.7M | $163.5M |
| Stockholders' equity | $230.9M | $201.2M | $242.6M | $417.8M | $715.1M |
| Cash and investments | $210.8M | $204.2M | $311.7M | $377.1M | $671.1M |
| Total debt | $3.1M | $3.9M | $10.6M | $10.9M | $17.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Oct 28, 2026 | Oct 28, 2026 |
| 6-K | Current report (foreign issuer) | Oct 26, 2026 | Oct 25, 2026 |
| 6-K | Current report (foreign issuer) | Oct 23, 2026 | Oct 23, 2026 |
| 6-K | Current report (foreign issuer) | Oct 13, 2026 | Oct 13, 2026 |
| 6-K | Current report (foreign issuer) | Sep 8, 2026 | Sep 8, 2026 |
| 6-K | Current report (foreign issuer) | Sep 8, 2026 | Sep 8, 2026 |
All 330 NovaBridge Biosciences SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.